{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:45:59Z","timestamp":1792197959622,"version":"4.4.0"},"reference-count":45,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":279,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>A number of herbal preparations have been shown to interact with prescription medications secondary to modulation of cytochrome P450 (CYP) and\/or P\u2010glycoprotein (P\u2010gp). The purpose of this study was to determine the influence of Panax ginseng on CYP3A and P\u2010gp function using the probe substrates midazolam and fexofenadine, respectively. Twelve healthy participants (8 men) completed this open\u2010label, single\u2010sequence pharmacokinetic study. Healthy volunteers received single oral doses of midazolam 8 mg and fexofenadine 120 mg, before and after 28 days of P ginseng 500 mg twice daily. Midazolam and fexofenadine pharmacokinetic parameter values were calculated and compared before and after P ginseng administration. Geometric mean ratios (postginseng\/preginseng) for midazolam area under the concentration\u2010time curve from zero to infinity (AUC<jats:sub>0\u2010\u221e<\/jats:sub>), half\u2010life (t<jats:sub>1\/2<\/jats:sub>), and maximum concentration (C<jats:sub>max<\/jats:sub>) were significantly reduced at 0.66 (0.55\u20130.78), 0.71 (0.53\u20130.90), and 0.74 (0.56\u20130.93), respectively. Conversely, fexofenadine pharmacokinetics were unaltered by P ginseng administration. Based on these results, P ginseng appeared to induce CYP3A activity in the liver and possibly the gastrointestinal tract. Patients taking P ginseng in combination with CYP3A substrates with narrow therapeutic ranges should be monitored closely for adequate therapeutic response to the substrate medication.<\/jats:p>","DOI":"10.1177\/0091270011407194","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T02:29:27Z","timestamp":1307413767000},"page":"932-939","source":"Crossref","is-referenced-by-count":115,"title":["Influence of<i>Panax ginseng<\/i>on Cytochrome P450 (CYP)3A and P\u2010glycoprotein (P\u2010gp) Activity in Healthy Participants"],"prefix":"10.1002","volume":"52","author":[{"given":"Christine Y.","family":"Malati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer D.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Chairez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul M.","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Penzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.18.1569"},{"key":"e_1_2_6_3_2","first-page":"42","article-title":"Trends in use of complementary and alternative medicine use by US adults: 1997\u20132002","volume":"11","author":"Tindle HA","year":"2005","journal-title":"Altern Ther Health Med"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X260871"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.8.797"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9146-8"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/11317010-000000000-00000"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.126913"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.39.1.1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408449209145319"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225050-00003"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-4526(08)00401-4"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2008.00868.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522060-00006"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003253636"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.09.013"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0944-7113(00)80044-6"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)90541-8b"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(99)00407-5"},{"key":"e_1_2_6_20_2","first-page":"86","article-title":"An open trial of nifedipine\u2010herb interactions: nifedipine with St. John's wort, ginseng, or Ginkgo biloba [abstract]","volume":"69","author":"Smith M","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121152"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-924-9:013"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfj164"},{"key":"e_1_2_6_24_2","article-title":"Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2, and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides","author":"Hao H","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"e_1_2_6_25_2","volume-title":"Guidance for Industry: Drug Interaction Studies\u2014Study Design, Data Analysis, and Implications for Dosing and Labeling","author":"US Department of Health and Human Services.","year":"2006"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/324351"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05712-8"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200004000-00001"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127002237986"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0762-z"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200112000-00006"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100105"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.3"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.199"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.140"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/11318000-000000000-00000"},{"key":"e_1_2_6_37_2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0090-9556(24)15235-X","article-title":"OATP and P\u2010glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine","volume":"27","author":"Cvetkovic M","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10264"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127002762491370"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80049-7"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113697"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.08.026"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02613.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.060194"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.017814"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.004622"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270011407194","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270011407194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:33:16Z","timestamp":1741221196000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270011407194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1177\/0091270011407194"],"URL":"https:\/\/doi.org\/10.1177\/0091270011407194","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}